Language
English
Publication Date
3-31-2025
Journal
Breast Cancer Research
DOI
10.1186/s13058-025-02006-9
PMID
40165290
PMCID
PMC11959873
PubMedCentral® Posted Date
3-31-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Breast cancer is the most prevalent cancer in women worldwide. Aberrant epigenetic reprogramming such as dysregulation of histone acetylation has been associated with the development of breast cancer. Histone acetylation modulators have been targeted as potential treatments for breast cancer. This review comprehensively discusses the roles of these modulators and the effects of their inhibitors on breast cancer. In addition, epigenetic reprogramming not only affects breast cancer cells but also the immunosuppressive myeloid cells, which can facilitate breast cancer progression. Therefore, the review also highlights the roles of these immunosuppressive myeloid cells and summarizes how histone acetylation modulators affect their functions and phenotypes. This review provides insights into histone acetylation modulators as potential therapeutic targets for breast cancer.
Keywords
Humans, Breast Neoplasms, Female, Acetylation, Histones, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Animals, Gene Expression Regulation, Neoplastic, Protein Processing, Post-Translational, Myeloid Cells, Antineoplastic Agents, Epigenetics, Histone acetylation, Myeloid cells
Published Open-Access
yes
Recommended Citation
Xueying Yuan and Jeffrey M Rosen, "Histone Acetylation Modulators in Breast Cancer" (2025). Faculty and Staff Publications. 4393.
https://digitalcommons.library.tmc.edu/baylor_docs/4393